Traders should monitor for potential downward pressure on the stock, especially if this selling continues. The concentration of sales among top executives, particularly the CEO, raises concerns about confidence in near-term prospects despite the relatively small percentage of market cap involved.
ZLAB drugs
ZLAB drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zai Lab's CEO Du Ying exercised and sold shares across multiple transactions, generating $1.92M from open-market sales. The activity was part of a broader insider cluster involving derivative exercises and sales, with the CEO accounting for the vast majority of the economic value. A senior legal executive also sold nearly $300K in stock.
Key Financial Metrics
Key Facts
- CEO Du Ying sold 100,000 shares in two open-market transactions for $1.92M ($951,465 on 2026-03-09 and $970,935 on 2026-03-06)
- Du Ying exercised 300,000 derivative securities across the week, with 150,000 at $0 and 150,000 at $1.74 strike price
- Chief Legal Officer Edmondson Frazor Titus III sold 15,569 shares for $296,745
- Total open-market sale value by insiders: $2.22M over 7 days
- All transactions occurred within a 7-day window, indicating coordinated activity
Financial Impact
$2.22M in insider sales, representing ~0.11% of ZLAB's $2.1B market cap
Risk Factors
- Perceived lack of confidence from top leadership, especially the CEO
- Potential for follow-on selling by other insiders
- Market interpretation of the activity as profit-taking ahead of uncertain catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-ZLAB-1773173329294 |
Track record
23 reports on ZLAB
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.13% at T+20 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
- Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers